

## Press Release

Lund, Sweden, January 24, 2019

### **ImmuneBiotech closes new share issue with funding from recognized international investors and business angels**

ImmuneBiotech AB, the probiotic and microbiome company developing and marketing science-based probiotics, is pleased to announce SEK 4.3 million (€0.43 million) investment in its recently completed financing. Due to the continuing interest from investors and business angels, the company intends to prolong its fund-raising into 2019.

A large portion of the funding will be used to commercialize its lead product GutMagnific™, a new scientifically designed probiotic food supplement for Irritable Bowel Syndrome (IBS), one of the most common gut conditions affecting 15 % of the population. ImmuneBiotech also plans to allocate funding to investigate the clinical effect of GutMagnific™.

“This new share issue has attracted international investors and once again confirms my belief in ImmuneBiotech as one of the most promising biotech companies in the hot new field of microbiome and probiotics. ImmuneBiotech has huge potential based on its unique know-how and expertise in designing science-based probiotics together with its access to a unique source of probiotic bacterial strains. Very few companies have this scientific approach to probiotic products.” said ImmuneBiotech's strategic advisor and Chairman Gregory Batcheller.

The lead investor, Mr. Michael McGeever, is well-known in the international probiotic and microbiome sector. “I’m excited to be onboard with the ImmuneBiotech team. IBS certainly needs a solution and ImmuneBiotech’s GutMagnific™ can be a big part of it. I also believe future products in the Companion Probiotics® line have the potential to be game-changers in this industry.” said Mike McGeever.

“It’s really fantastic to see our 15 years of scientific work now being translated into a product that truly helps people suffering with difficult conditions. Our mission is to make it available to the consumers as soon as possible. Starting with a successful Seed Round and this Series A funding, the company raised about 7 million SEK during 2018 and we couldn’t be more excited about our funding partnerships” said Shahram Lavasani, CEO of ImmuneBiotech.

### **About ImmuneBiotech AB**

ImmuneBiotech discovers and markets science-based probiotic food supplements. Based on our multi-disciplinary scientific foundation, we deliver innovative probiotic products scientifically designed to modulate the gut microbiota, reduce gut permeability and act anti-inflammatory.



### **About GutMagnific™**

GutMagnific™ is a super-consortium of five probiotic strains scientifically designed to address the underlying key causes of IBS. It is a patent pending combination of proprietary lactobacillus strains and will be sold as a food supplement supported by clinical data. GutMagnific™ has potential application in several severe and prevalent conditions such as IBS, diarrhea, antibiotic induced diarrhea, *Clostridium difficile* infection (CDI) and Chronic Fatigue Syndrome (ME/CFS). It has also the ability to target symptoms such as leaky gut and small intestine bacterial overgrowth (SIBO).

### **About IBS**

IBS is the most common gastrointestinal disorder, occurring in up to 10-15% of the population. It is a functional disorder of the digestive tract causing abdominal pain, bloating, constipation and/or diarrhea, and is often associated with depression. IBS patients are in general under-diagnosed and often self-managed they are looking for alternative solutions. There is a significant unmet need for safe products with good efficacy. Available products show only moderate efficacy, and they only address symptoms e.g. pain, diarrhea or constipation.

Shahram Lavasani, CEO  
s.lavasani@immunebiotech.com  
+46 707 40 86 61  
ImmuneBiotech AB